| Marjorie Ann Demund, MD | |
|
1220 E Elm St Ste 101, Lima, OH 45804-2803 | |
| (419) 998-8245 | |
| (419) 998-8247 |
| Full Name | Marjorie Ann Demund |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 40 Years |
| Location | 1220 E Elm St Ste 101, Lima, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063464873 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lima Memorial Health System | Lima, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lima Memorial Professional Corporation | 1254232184 | 135 |
News Archive
Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.
If the immune system attacks its own body, it can often have devastating consequences: autoantibodies bind to the body's structures, triggering functional disorders.
Artificial intelligence (AI) is able to recognize the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.
› Verified 8 days ago
| Entity Name | North East Ohio Group Practice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063575462 PECOS PAC ID: 8426960618 Enrollment ID: O20031105000352 |
News Archive
Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.
If the immune system attacks its own body, it can often have devastating consequences: autoantibodies bind to the body's structures, triggering functional disorders.
Artificial intelligence (AI) is able to recognize the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.
› Verified 8 days ago
| Entity Name | Lima Memorial Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457474900 PECOS PAC ID: 1254232184 Enrollment ID: O20040115000131 |
News Archive
Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.
If the immune system attacks its own body, it can often have devastating consequences: autoantibodies bind to the body's structures, triggering functional disorders.
Artificial intelligence (AI) is able to recognize the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.
› Verified 8 days ago
| Entity Name | Ashtabula County Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942247143 PECOS PAC ID: 2668465600 Enrollment ID: O20040406000897 |
News Archive
Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.
If the immune system attacks its own body, it can often have devastating consequences: autoantibodies bind to the body's structures, triggering functional disorders.
Artificial intelligence (AI) is able to recognize the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marjorie Ann Demund, MD 1001 Bellefontaine Ave, Lima, OH 45804-2800 Ph: (419) 226-5018 | Marjorie Ann Demund, MD 1220 E Elm St Ste 101, Lima, OH 45804-2803 Ph: (419) 998-8245 |
News Archive
Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.
If the immune system attacks its own body, it can often have devastating consequences: autoantibodies bind to the body's structures, triggering functional disorders.
Artificial intelligence (AI) is able to recognize the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.
› Verified 8 days ago
Dr. Maurice K Chung, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 310 S Cable Rd, Lima, OH 45805 Phone: 419-228-1000 Fax: 419-227-3085 | |
Dr. Scott C. Stallkamp, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 830 W High St, Ste 101, Lima, OH 45801 Phone: 419-227-0610 Fax: 419-228-3273 | |
Dr. Rhonda J Medina, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1220 E Elm St Ste 101, Lima, OH 45804 Phone: 419-998-8245 Fax: 419-998-8247 | |
Dr. Charles R Ryan, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 830 W High St, Ste 101, Lima, OH 45801 Phone: 419-227-0610 Fax: 419-228-3273 | |
Elizabeth Read Rumschlag, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 830 W High St Ste 101, Lima, OH 45801 Phone: 419-227-9354 Fax: 419-227-9354 | |
Darcy Langhals, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 830 W High St Ste 101, Lima, OH 45801 Phone: 419-227-0610 Fax: 419-228-3273 |